Ward E Sally, Devanaboyina Siva Charan, Ober Raimund J
Department of Molecular and Cellular Medicine, Texas A&M Health Science Center, College Station, TX 77843-1114, USA; Department of Microbial Pathogenesis and Immunology, Texas A&M Health Science Center, College Station, TX 77843-1114, USA; Department of Immunology, University of Texas Southwestern Medical Center, 6001 Forest Park Road, Dallas, TX 75390-9093, USA.
Department of Immunology, University of Texas Southwestern Medical Center, 6001 Forest Park Road, Dallas, TX 75390-9093, USA.
Mol Immunol. 2015 Oct;67(2 Pt A):131-41. doi: 10.1016/j.molimm.2015.02.007. Epub 2015 Mar 9.
The MHC class I-related receptor, FcRn, is a multitasking protein that transports its IgG ligand within and across cells of diverse origins. The role of this receptor as a global regulator of IgG homeostasis and transport, combined with knowledge of the molecular details of FcRn-IgG interactions, has led to opportunities to modulate the in vivo dynamics of antibodies and their antigens through protein engineering. Consequently, the generation of half-life extended antibodies has shown a rapid expansion over the past decade. Further, FcRn itself can be targeted by inhibitors to induce decreased levels of circulating IgGs, which could have applications in multiple clinical settings. The engineering of antibody-antigen interactions to reduce antibody-mediated buffering of soluble ligand has also developed into an active area of investigation, leading to novel antibody platforms designed to result in more effective antigen clearance. Similarly, the target-mediated elimination of antibodies by internalizing, membrane bound antigens (receptors) can be decreased using novel engineering approaches. These strategies, combined with subcellular trafficking analyses of antibody/antigen/FcRn behavior in cells to predict in vivo behavior, have considerable promise for the production of next generation therapeutics and diagnostics.
主要组织相容性复合体I类相关受体FcRn是一种多功能蛋白质,可在多种来源的细胞内及细胞间转运其IgG配体。该受体作为IgG稳态和转运的全局调节因子的作用,以及对FcRn-IgG相互作用分子细节的了解,为通过蛋白质工程调节抗体及其抗原的体内动力学创造了机会。因此,在过去十年中,半衰期延长抗体的产生迅速增加。此外,FcRn本身可被抑制剂靶向,以降低循环IgG的水平,这可能在多种临床环境中得到应用。通过工程改造抗体-抗原相互作用以减少抗体介导的可溶性配体缓冲作用,也已发展成为一个活跃的研究领域,催生了旨在实现更有效抗原清除的新型抗体平台。同样,使用新型工程方法可以减少内化的膜结合抗原(受体)对抗体的靶向介导清除。这些策略,结合对细胞内抗体/抗原/FcRn行为的亚细胞运输分析以预测体内行为,对于下一代治疗药物和诊断方法的生产具有相当大的前景。